BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Convergence Pharmaceuticals 

Babraham Research Campus

Cambridge    CB22 3AT  United Kingdom
Phone: +44-(0)1223-755-501 Fax: +44-(0)1223-497-114


SEARCH JOBS




Industry
Pharmaceutical

Segment
Pharmaceuticals





 Company News
Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy And Safety In Ground-Breaking Phase II Trigeminal Neuralgia Study 6/16/2014 7:43:14 AM
GlaxoSmithKline (GSK) Spin-Off Convergence Pharmaceuticals Gears Up For Possible Listing 6/16/2014 6:30:13 AM
Evotec AG (EVTG.F) And Convergence Pharmaceuticals Form Integrated Pain Alliance 3/31/2014 10:10:41 AM
Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802 7/30/2013 8:14:54 AM
Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Post-Herpetic Neuralgia 7/8/2013 9:54:48 AM
Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated With Post-Herpetic Neuralgia 4/23/2013 9:48:49 AM
Convergence Pharmaceuticals Announces Successful Interim Data From Ground-Breaking Phase II Trigeminal Neuralgia Study 3/27/2013 9:26:32 AM
Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain 7/18/2012 10:08:05 AM
Convergence Pharmaceuticals Announces Start of Phase II Study for CNV1014802 for Trigeminal Neuralgia 3/19/2012 9:06:50 AM
Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 11/21/2011 7:17:17 AM
12